Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (2) | Back to Search
Quorum sensing inhibitors for pulmonary delivery as a novel treatment against Pseudomonas aeruginosa
- In: Short Communications B1 on Monday, 22 May 2017, 13:30-15:00
- At: Stockholm (Sweden) (2017)
- Type: Presentation
- By: SOU, Tomás (Uppsala University, Pharmacy, Uppsala, Sweden)
- Co-author(s): Tomás Sou: Department of Pharmacy, Uppsala University, Uppsala, Sweden
Christel Bergström: Department of Pharmacy, Uppsala University, Uppsala, Sweden
Miguel Cámara: School of Life Sciences, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, United Kingdom
Fadi Soukarieh: School of Life Sciences, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, United Kingdom
Michael Stocks: School of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, United Kingdom
Paul Williams: School of Life Sciences, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, United Kingdom
Irena Kukavica-Ibrulj: Institut de biologie intégrative et des systèmes, Université Laval, Québec, Canada
Roger C. Levesque: Institut de biologie intégrative et des systèmes, Université Laval, Québec, Canada - Abstract:
Backgrounds
Pseudomonas aeruginosa exhibits a high rate of resistance to many of the current therapies available. A novel class of anti-virulence agents, quorum sensing inhibitors (QSI), designed to suppress biofilm formation in P. aeruginosa, and therefore sensitise the bacteria to other antibiotic treatments, is currently being developed.
Aims
To
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023